CoChat
Sign Up
Cited by 862

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Potential therapeutic applications of autophagy

Rubinsztein, David C., Gestwicki, Jason E., Murphy, Leon O., Klionsky, Daniel J.·2007·Nature Reviews Drug Discovery
DOI 10.1038/nrd2272
Open this paper in CoChat — free account

Abstract

Autophagy is a dynamic process of subcellular degradation, which has recently sparked great interest as it is now recognized to be involved in various developmental processes and various diseases including cancer and neurodegeneration. Autophagy can function as a cytoprotective mechanism; however, it also has the capacity to cause cell death. A better understanding of autophagy is needed to allow its manipulation for therapeutic purposes, and new insights into the molecular mechanisms of autophagy are now leading to the discovery of exciting new potential drug targets.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd2272

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Autophagic flux dysfunction contributes to AD, PD, HD, and ALS.

    “Autophagic flux, encompassing autophagosome formation, maturation, lysosomal fusion, and degradation, is essential for neuronal homeostasis, and its dysfunction contributes to AD, PD, HD, and ALS (Williams et al. 2006), (Rubinsztein et al. 2007), (Wong and Cuervo 2010).”

    From TMEM55B downregulation promotes neurodegeneration in Alzheimer’s disease models (2026) · cites this paper as Rubinsztein et al. 2007

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 74

  1. Tallóczy, Z., Virgin, H. W. IV & Levine, B. PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2, 24–29 (2006). · DOI · Paper page
  2. Rubinsztein, D. C. et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1, 11–22 (2005). · DOI
  3. Botti, J., Djavaheri-Mergny, M., Pilatte, Y. & Codogno, P. Autophagy signaling and the cogwheels of cancer. Autophagy 2, 67–73 (2006). · DOI
  4. Jin, S. Autophagy, mitochondrial quality control, and oncogenesis. Autophagy 2, 80–84 (2006). · DOI
  5. Levine, B. Unraveling the role of autophagy in cancer. Autophagy 2, 65–66 (2006). · DOI
  6. Birmingham, C. L. & Brumell, J. H. Autophagy recognizes intracellular Salmonella enterica serovar Typhimurium in damaged vacuoles. Autophagy 2, 156–158 (2006). · DOI · Paper page
  7. Colombo, M. I., Gutierrez, M. G. & Romano, P. S. The two faces of autophagy: Coxiella and Mycobacterium. Autophagy 2, 162–164 (2006). · DOI · Paper page
  8. Dubuisson, J. F. & Swanson, M. S. Mouse infection by Legionella, a model to analyze autophagy. Autophagy 2, 179–182 (2006). · DOI
  9. Ogawa, M. & Sasakawa, C. Shigella and autophagy. Autophagy 2, 171–174 (2006). · DOI
  10. Vergne, I. et al. Autophagy in immune defense against Mycobacterium tuberculosis. Autophagy 2, 175–178 (2006). · DOI · Paper page
  11. Webster, P. Cytoplasmic bacteria and the autophagic pathway. Autophagy 2, 159–161 (2006). · DOI
  12. Yoshimori, T. Autophagy vs. group A Streptococcus. Autophagy 2, 154–155 (2006). · DOI · Paper page
  13. Klionsky, D. J. Autophagy (Landes Bioscience, Georgetown, 2004).
  14. Wang, C.-W. & Klionsky, D. J. The molecular mechanism of autophagy. Mol. Med. 9, 65–76 (2003). · DOI
  15. Massey, A. C., Zhang, C. & Cuervo, A. M. Chaperone-mediated autophagy in aging and disease. Curr. Top. Dev. Biol. 73, 205–235 (2006). · DOI · Paper page
  16. Yorimitsu, T. & Klionsky, D. J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 12, 1542–1552 (2005). · DOI
  17. Klionsky, D. J. et al. A unified nomenclature for yeast autophagy-related genes. Dev. Cell 5, 539–545 (2003). · DOI
  18. Reggiori, F. & Klionsky, D. J. Autophagy in the eukaryotic cell. Eukaryot. Cell 1, 11–21 (2002). · DOI
  19. Ohsumi, Y. & Mizushima, N. Two ubiquitin-like conjugation systems essential for autophagy. Semin. Cell Dev. Biol. 15, 231–236 (2004). · DOI
  20. Nair, U. & Klionsky, D. J. Molecular mechanisms and regulation of specific and nonspecific autophagy pathways in yeast. J. Biol. Chem. 280, 41785–41788 (2005). · DOI · Paper page
  21. Petiot, A., Ogier-Denis, E., Blommaart, E. F., Meijer, A. J. & Codogno, P. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 275, 992–998 (2000). · DOI
  22. Young, A. R. J. et al. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J. Cell Sci. 119, 3888–3900 (2006). · DOI · Paper page
  23. Noda, T. et al. Apg9p/Cvt7p is an integral membrane protein required for transport vesicle formation in the Cvt and autophagy pathways. J. Cell Biol. 148, 465–480 (2000). · DOI
  24. Blommaart, E. F., Luiken, J. J., Blommaart, P. J., van Woerkom, G. M. & Meijer, A. J. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. 270, 2320–2326 (1995). · DOI · Paper page
  25. Kamada, Y. et al. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J. Cell Biol. 150, 1507–1513 (2000). · DOI · Paper page
  26. Klionsky, D. J., Meijer, A. J., Codogno, P., Neufeld, T. P. & Scott, R. C. Autophagy and p70S6 kinase. Autophagy 1, 59–61 (2005). · DOI
  27. Noda, T. & Ohsumi, Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 273, 3963–3966 (1998). · DOI
  28. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nature Rev. Cancer 4, 335–348 (2004). · DOI
  29. Galanis, E. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294–5304 (2005). · DOI
  30. Lee, V. W. & Chapman, J. R. Sirolimus: its role in nephrology. Nephrology (Carlton) 10, 606–614 (2005). · DOI
  31. Frias, M. A. et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16, 1865–1870 (2006). · DOI
  32. Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006). · DOI · Paper page
  33. Sarkar, S. et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101–1111 (2005). This paper describes a novel mTOR-independent pathway for inducing autophagy. This pathway, which is negatively regulated by IP 3 levels, can be activated by commonly used drugs such as lithium, carbemazepine and sodium valproate. Thus, these drugs might have clinical utility for autophagy upregulation. · DOI · Paper page
  34. Berridge, M. J. Unlocking the secrets of cell signaling. Annu. Rev. Physiol. 67, 1–21 (2005). · DOI
  35. Menzies, F. M., Ravikumar, B. & Rubinsztein, D. C. Protective roles for induction of autophagy in multiple proteinopathies. Autophagy 2, 224–225 (2006). · DOI · Paper page
  36. Sanchez, I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373–379 (2003). · DOI
  37. Ravikumar, B., Duden, R. & Rubinsztein, D. C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107–1117 (2002). This was the first study that suggested that aggregate-prone intracytosolic proteins, such as mutant huntingtin fragments, are dependent on autophagy for their clearance. It also provides the 'proof-of-principle' for protective effects of autophagy upregulation in cell models of Huntington's disease. · DOI
  38. Iwata, A. et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl Acad. Sci. USA 102, 13135–13140 (2005). · DOI
  39. Qin, Z. H. et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum. Mol. Genet. 12, 3231–3244 (2003). · DOI
  40. Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433–442 (2006). · DOI · Paper page
  41. Kabuta, T., Suzuki, Y. & Wada, K. Degradation of amyotrophic lateral sclerosis-linked mutant Cu, Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J. Biol. Chem. 281, 30524–30533 (2006). · DOI
  42. Fortun, J., Dunn, W. A., Jr., Joy, S., Li, J. & Notterpek, L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J. Neurosci. 23, 10672–10680 (2003). · DOI
  43. Komatsu, M. et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880–884 (2006). This study shows that the targeted disruption of ATG7 (which blocks autophagy) in neuronal cells results in formation of inclusion bodies and neurodegeneration. This study was published together with reference 56, and the two papers provide compelling and complementary evidence that basal autophagy is crucial for neuronal survival. · DOI · Paper page
  44. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57–66 (2000). · DOI
  45. Ravikumar, B., Berger, Z., Vacher, C., O'Kane, C. J. & Rubinsztein, D. C. Rapamycin pre-treatment protects against apoptosis. Hum. Mol. Genet. 15, 1209–1216 (2006). · DOI
  46. Kessel, D. & Reiners, J. J. Jr. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett. 18 Oct 2006 (doi:10.1016/j.canlet.2006.09.009). · DOI
  47. Saeki, K. et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ. 7, 1263–1269 (2000). · DOI
  48. Verhoef, L. G., Lindsten, K., Masucci, M. G. & Dantuma, N. P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 11, 2689–2700 (2002). · DOI
  49. Nakagawa, I. et al. Autophagy defends cells against invading group A Streptococcus. Science 306, 1037–1040 (2004). This paper shows that autophagy can help to eliminate group A Streptococci in non-phagocytic cells. · DOI
  50. Kirkegaard, K., Taylor, M. P. & Jackson, W. T. Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nature Rev. Microbiol. 2, 301–314 (2004). · DOI
  51. Jin, S. p53, autophagy and tumor suppression. Autophagy 1, 171–173 (2005). · DOI
  52. Hippert, M. M., O' Toole P, S. & Thorburn, A. Autophagy in cancer: good, bad, or both? Cancer Res. 66, 9349–9351 (2006). · DOI
  53. Shintani, T. & Klionsky, D. J. Autophagy in health and disease: a double-edged sword. Science 306, 990–995 (2004). · DOI
  54. Wienecke, R. et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am. J. Kidney Dis. 48, e27–e29 (2006). · DOI
  55. Furuya, N., Liang, X. H. & Levine, B. in Autophagy (ed. Klionsky, D. J.) 241–255 (Landes Bioscience, Georgetown, 2004).
  56. Amaravadi, R. K. et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. (2007). This paper suggests that autophagy inhibition enhances various pro-apoptotic chemotherapeutic strategies that might be of value in treating certain cancers. · DOI
  57. Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240–4245 (1999). · DOI
  58. Liu, Z. & Roberts, T. M. Human tumor mutants in the p110α subunit of PI3K. Cell Cycle 5, 675–677 (2006). · DOI
  59. Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194–204 (2005). · DOI
  60. Ward, S. G. & Finan, P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3, 426–434 (2003). · DOI
  61. Degenhardt, K. et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10, 51–64 (2006). · DOI
  62. Lum, J. J. et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120, 237–248 (2005). Bax−/−Bak −/− cells activate autophagy, undergo progressive atrophy, and eventually die after growth factor withdrawal. This study shows that autophagy is a protective response against cell death in this context. · DOI · Paper page
  63. Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006). · DOI · Paper page
  64. Fan, Q. W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006). · DOI
  65. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926–1945 (2004). · DOI · Paper page
  66. Boya, P. et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 25, 1025–1040 (2005). This study reports that mammalian cells are much more likely to die after growth factor withdrawal if autophagy is inhibited. · DOI
  67. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005). · DOI
  68. Leung-Toung, R. et al. Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem. 13, 547–581 (2006). · DOI
  69. Kumanomidou, T. et al. The crystal structure of human Atg4b, a processing and de-conjugating enzyme for autophagosome-forming modifiers. J. Mol. Biol. 355, 612–618 (2006). · DOI
  70. Knight, Z. A. & Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 12, 621–637 (2005). · DOI
  71. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782–1788 (1995). · DOI
  72. Berg, T. Modulation of protein-protein interactions with small organic molecules. Angew. Chem. Int. Ed. Engl. 42, 2462–2481 (2003). · DOI
  73. Gestwicki, J. E., Crabtree, G. R. & Graef, I. A. Harnessing chaperones to generate small-molecule inhibitors of amyloid β aggregation. Science 306, 865–869 (2004). · DOI
  74. Toogood, P. L. Inhibition of protein–protein association by small molecules: approaches and progress. J. Med. Chem. 45, 1543–1558 (2002). · DOI

Cited by

Sorted by citations

Metadata

Authors
Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O., & Klionsky, D. J.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2007-04
Volume
6
Issue
4
Pages
304-312
ISSN
  • 1474-1776
  • 1474-1784
DOI
10.1038/nrd2272
Cited by
862
References
18
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review